T cells and COVID Vaccine

Anele Jones

Biomedical Science

BIO 302: Introduction to Immunology

15 November 2024

The development of the coronavirus took the world by surprise in 2019. However, with this, the development of vaccines, specifically targeting COVID-19, was also introduced rapidly. With this, many people, even the scientists who may have developed these vaccines, don't have a full understanding of all the background mechanisms behind it. In the article titled “T- T-Cell Immunity to COVID-19 Vaccines”, the author identifies breaks down, and analyzes the evidence of efficiency connected to neutralizing antibodies and the crucial role that T-cell responses play in protecting not only the base disease, but its variants such as SARS-CoV-2, omicron, and many more. The article answers three main questions regarding the efficiency of T cell responses in correlation to COVID-19; what are T cells?, how can antibody responses be prevented with the use of T cells?, How does the type of adaptive (humoral or cellular) immunity affect how intensely the immune system will react and heal?

To develop a true understanding of how T-cell responses in vaccines work, we must understand the differences in types of adaptive immunity, which don’t correlate to vaccinations. First, the article notes humoral immunity, which involves antibodies and memory B cells. While the author doesn't directly define humoral immunity, we can define this as a defense mechanism that produces antibodies that neutralize toxins and bacteria or simply eliminate them (2). When we look at cellular immunity, we see the use of CD4+ T helper cells and CD8+ cytotoxic T cells. These T cells target infected cells and limit the ability of the virus to replicate and spread, without killing them on site. This type of immunity supports the idea that T cells are crucial in mitigating the severity of diseases (2).

These results were concluded by identifying the use of T cells in more severe forms of disease such as cancer and only begin to work in 4 to 6 months. Now when we think of its distinct connection to the treatment of coronavirus, there are a few studies highlighted in the

article. Research in cancer patients with B cell deficiencies revealed that CD8+ T cell responses were associated with milder disease outcomes. Macaque studies demonstrated that depletion of CD8+ T cells led to more severe disease after SARS-CoV-2 exposure. Data from the Omicron wave, where neutralizing antibodies were less effective, still showed that people with robust T cell responses were less likely to experience severe disease, supporting the hypothesis that T cells can help mitigate disease severity even in the absence of high NAb titers (2).

When discussing COVID-19 symptoms, one of the biggest ones is mucous congestion in the lungs and the throat. Due to this, there is continuous interest in generating long-lasting memory T cells that can reside in these mucus sites of infection. This would provide more immediate protection at the entry points of the virus (2).

The article suggests that despite the progress made, there are still things that remain unknown. One of the main questions is how best to monitor and measure T-cell responses to understand the efficiency of the vaccines. The role of T cells residing in mucous and the long-term durability of vaccine-induced T cell memory are still being researched. While current boosters have been shown to improve neutralizing antibody titers against specific variants like Omicron, the impact on T-cell responses remains less understood. It is crucial to define the precise mechanisms by which T cells contribute to vaccine protection and to identify optimal methods for enhancing these responses in future vaccine strategies (2).

In conclusion, the article provides a conclusive understanding that T cells play a critical role in protecting against severe COVID-19, especially as variants like Omicron challenge the efficacy of neutralizing antibodies. Current vaccines, though primarily designed to induce antibody responses, also generate durable T-cell immunity that contributes significantly to preventing severe diseases such as cancer. The author implies that continued research and

vaccine development will be centered on enhancing T-cell responses and expanding the range of viral targets to ensure long-term protection against SARS-CoV-2 and other infectious diseases. Understanding the interplay between humoral and cellular immunity will be key to optimizing vaccine strategies and improving global health outcomes in the face of evolving viral threats (2).

Works Cited

1. Wherry, E. J. (2022, August 18). *T cell immunity to covid-19 vaccines*. Science. https://www.science.org/doi/10.1126/science.add2897
2. Wira, C. R. (2012, November 5). *Mucosal immunity in the human reproductive tract: Balancing reproductive potential with protection against sexually transmitted pathogens*. Sexually Transmitted Diseases (Second Edition). https://www.sciencedirect.com/science/article/abs/pii/B9780123910592000036